P. Meraviglia

发表

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

D. Podzamczer, B. Clotet, A. Winston, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral treatment and age‐related comorbidities in a cohort of older HIV‐infected patients

A. Riva, A. Zambelli, L. Cordier, 2006, HIV medicine.

Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.

E. Clementi, D. Cattaneo, G. Rizzardini, 2012, Pharmacological research.

Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients

E. Clementi, A. Giacomelli, M. Galli, 2017, BMC Infectious Diseases.

Lack of clinically relevant interactions between bictegravir and metformin in persons with diabetes and HIV.

D. Cattaneo, C. Gervasoni, P. Meraviglia, 2021, The Journal of antimicrobial chemotherapy.

96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience

M. Meschiari, S. Lo Caputo, E. Ricci, 2012, PloS one.

Prevalence and factors associated with idiopathic hypercalciuria in HIV patients on combination antiretroviral therapy

E. Ricci, P. Bonfanti, G. Rizzardini, 2010, International Journal of STD and AIDS.

ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment

E. Clementi, A. de Silvestri, D. Cattaneo, 2021, The Pharmacogenomics Journal.

Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?

E. Clementi, D. Cattaneo, N. Charbe, 2015, PloS one.

Atypical pharmacokinetics of atazanavir in an HIV‐1‐infected patient

E. Clementi, D. Cattaneo, S. Baldelli, 2012, Fundamental & clinical pharmacology.

Virologic failure in an HIV-infected woman given desogestrel for excessive menstrual bleeding

E. Clementi, D. Cattaneo, R. Beretta, 2011, European Journal of Clinical Pharmacology.

Lopinavir/Ritonavir Pharmacokinetics in HIV/HCV-Coinfected Patients With or Without Cirrhosis

S. Khoo, P. Duca, D. Back, 2008, Therapeutic drug monitoring.

When the absence of an interaction can become clinically relevant.

D. Cattaneo, C. Gervasoni, Chiara Resnati, 2021, AIDS.

The Relevance of Drug–drug Interactions in Clinical Practice: The Case of Concomitant Boosted Protease Inhibitors plus Alpha-1 Blocker Administration

D. Cattaneo, C. Gervasoni, Chiara Resnati, 2018, Antiviral therapy.

Incidence and risk factors of major cardiovascular events in a multicentre HIV cohort

L. Valsecchi, G. Rizzardini, B. Menzaghi, 2012 .

Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Phase 1 Study

E. Clementi, D. Cattaneo, A. Riva, 2015, Therapeutic drug monitoring.

Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by Chewing

E. Clementi, D. Cattaneo, A. Gazzaniga, 2012, Antimicrobial Agents and Chemotherapy.

Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV‐Infected Patients

E. Clementi, D. Cattaneo, D. Ripamonti, 2012, Journal of clinical pharmacology.

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.

E. Clementi, D. Cattaneo, M. Galli, 2012, The Journal of antimicrobial chemotherapy.

Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial

G. d’Ettorre, M. Colafigli, P. Vitiello, 2013, PloS one.

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART

A. di Pietro, G. d’Ettorre, P. Vitiello, 2010, Journal of the International AIDS Society.

Pandemic influenza vaccine in adult HIV-1-infected patients.

E. Pariani, E. Tanzi, A. Zanetti, 2010, AIDS.

Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index.

F. del Sorbo, E. Angeli, L. Cordier, 2002, AIDS.

Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF

E. Clementi, A. Giacomelli, D. Cattaneo, 2017, Journal of acquired immune deficiency syndromes.

One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG

G. Rizzardini, A. Capetti, D. Mileto, 2021, Journal of Infection.

Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis

E. Clementi, A. Giacomelli, D. Cattaneo, 2019, Clinical Pharmacokinetics.

Reduction of Homologous Transfusions in Open-Heart Surgery

S. Guzzetti, P. Meraviglia, C. Santoli, 1992 .

Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.

M. Clerici, M. Biasin, D. Trabattoni, 2011, Blood.

Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events

E. Clementi, D. Cattaneo, A. Riva, 2013, PloS one.

Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.

M. Meschiari, S. Lo Caputo, E. Ricci, 2014, International journal of antimicrobial agents.

When food can make the difference: The case of elvitegravir-based co-formulation.

E. Clementi, D. Cattaneo, M. Galli, 2016, International journal of pharmaceutics.

Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy

M. Clerici, A. Gori, D. Trabattoni, 2010, AIDS.

Secondary hyperparathyroidism in HIV patients: is there any responsibility of highly active antiretroviral therapy?

E. Ricci, P. Bonfanti, G. Rizzardini, 2011, AIDS.

Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens.

S. Antinori, D. Cattaneo, C. Gervasoni, 2021, AIDS.

Determinants of bone diseases in tenofovir-treated HIV patients.

E. Clementi, D. Cattaneo, G. Rizzardini, 2016, AIDS.

Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice

E. Clementi, A. Giacomelli, D. Cattaneo, 2018, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Clinical features and outcomes of HIV patients with coronavirus disease 2019

A. Giacomelli, D. Cattaneo, A. Riva, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users

M. Zazzi, A. De Luca, M. Ciccozzi, 2016, PloS one.

HIV-1 Subtype F1 Epidemiological Networks among Italian Heterosexual Males Are Associated with Introduction Events from South America

M. Zazzi, A. De Luca, M. Ciccozzi, 2012, PloS one.

Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.

R. Maserati, M. Zazzi, M. Colafigli, 2009, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

A. Monforte, P. Cicconi, A. di Biagio, 2005, International journal of antimicrobial agents.

Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).

R. Maserati, M. Zazzi, D. Francisci, 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Eligibility and feasibility of the treatment of chronic hepatitis C in a Cohort of Italian HIV-positive patients at a single HIV reference center.

E. Ricci, E. Angeli, G. Rizzardini, 2011, AIDS patient care and STDs.

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial

P. Narciso, A. Lazzarin, A. Giacomelli, 2018, The Journal of antimicrobial chemotherapy.

Brief Report: Impact of the COVID-19 Pandemic on Virological Suppression in People Living With HIV Attending a Large Italian HIV Clinic

A. Giacomelli, S. Antinori, M. Galli, 2021, Journal of acquired immune deficiency syndromes.

Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individuals.

M. Gismondo, G. Zehender, C. Balotta, 2012, AIDS research and human retroviruses.

Pretreatment HIV drug Resistance and Treatment Failure in Non-Italian HIV-1-Infected Patients Enrolled in ARCA

Domenico Di Carlo, E. Pontali, S. Di Giambenedetto, 2020, Antiviral therapy.

Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV

D. Cattaneo, C. Spinner, C. Hoffmann, 2020, HIV medicine.

Does the co-morbidity burden contribute to suboptimal immunological responses to COVID-19 vaccination in people living with HIV?

A. Giacomelli, S. Antinori, Francesco Petri, 2022, The Journal of infectious diseases.

High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype.

A. De Luca, C. Balotta, P. Bagnarelli, 2012, The Journal of antimicrobial chemotherapy.

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings

C. Fìlice, D. Cattaneo, L. Milazzo, 2020, Drugs in R&D.

Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.

A. Monforte, P. Cicconi, F. Adorni, 2006, AIDS research and human retroviruses.

Virological Success of Lopinavir/Ritonavir Salvage Regimen is Affected by an Increasing Number of Lopinavir/Ritonavir-Related Mutations

A. Monforte, P. Cicconi, F. Adorni, 2002, Antiviral therapy.

Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19

A. Giacomelli, D. Cattaneo, A. Riva, 2020 .

A perspective Italian study on HIV-1 resistance in naive patients for antiretroviral therapy

M. Gismondo, V. Micheli, L. Valsecchi, 2001 .

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

G. Filice, M. Zazzi, A. De Luca, 2011, Journal of medical virology.

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study

A. Antinori, C. Mussini, A. Monforte, 2016, Drug design, development and therapy.

cART durability and causes for treatment switching or discontinuation in HIV-positive patients older than 50 years of age.

E. Ricci, E. Angeli, A. Zambelli, 2010, Journal of acquired immune deficiency syndromes.

Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice

A. d’Arminio Monforte, E. Foglia, L. Ferrario, 2020, Health Economics Review.

Reply to Childs et al.

D. Cattaneo, C. Gervasoni, P. Meraviglia, 2020, Clinical Infectious Diseases.

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.

D. Podzamczer, B. Clotet, A. Winston, 2020, The Journal of antimicrobial chemotherapy.

Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals

M. Clerici, M. Biasin, E. Ricci, 2013, AIDS.

Lopinavir/ritonavir treatment in HIV antiretroviral‐experienced patients: evaluation of risk factors for liver enzyme elevation

P. Duca, A. Castagna, E. Angeli, 2004, HIV medicine.

Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens?

G. Rizzardini, A. Capetti, S. Digiambenedetto, 2019, Open forum infectious diseases.

Dolutegravir Plasma Concentrations According to Companion Antiretroviral Drug: Unwanted Drug Interaction or Desirable Boosting Effect?

E. Clementi, D. Cattaneo, A. Riva, 2017, Antiviral therapy.

Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV‐1 subtype C epidemics

M. Zazzi, A. De Luca, M. Ciccozzi, 2014, Journal of medical virology.

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

R. Maserati, M. Zazzi, A. De Luca, 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Polypharmacy and Aging in People Living with HIV: 6 Years of Experience in a Multidisciplinary Outpatient Clinic

S. Antinori, D. Cattaneo, A. Gori, 2023, Drugs & Aging.

Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.

A. d’Arminio Monforte, P. Cicconi, A. di Biagio, 2005, The Journal of antimicrobial chemotherapy.

Interpretation of Genotypic Resistance to Predict Darunavir/Ritonavir Failure in Antiretroviral Experienced Patients

M. Zazzi, A. De Luca, V. Borghi, 2012, Journal of acquired immune deficiency syndromes.

HIV+ patients and gender differences: evidence from an Italian cohort

E. Foglia, L. Ferrario, D. Croce, 2016 .

Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.

D. Cattaneo, A. Riva, M. Galli, 2013, The Journal of antimicrobial chemotherapy.

HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications.

M. Andreoni, D. Ripamonti, A. Giacometti, 2012, European review for medical and pharmacological sciences.

Association of HIV Infection with Epilepsy and Other Comorbid Conditions

A. Giacomelli, D. Cattaneo, C. Gervasoni, 2019, Aids and Behavior.

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

R. Maserati, M. Zazzi, P. Vitiello, 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009.

M. Prosperi, M. Zazzi, S. Paolucci, 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV‐1 subtype C epidemics

M. Zazzi, A. De Luca, M. Ciccozzi, 2014, Journal of medical virology.

PLOS ONE HIV-1 A1 subtype epidemic in Italy originated from Africa and Eastern Europe and shows a high frequency of transmission chains involving intravenous drug users

M. Zazzi, M. Ciccozzi, --Manuscript Draft, 2015 .

Evolution of transmitted HIV‐1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

M. Gismondo, O. Turriziani, M. Zazzi, 2018, HIV medicine.

How relevant are the drug–drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life?

D. Cattaneo, C. Gervasoni, A. Ridolfo, 2018, The Journal of antimicrobial chemotherapy.